Baillie Gifford U.S. Growth Trust devoted much of its half-yearly report to talking up the prospects of biotech Moderna and rocket launcher SpaceX, two of its investments that helped lift its net asset value surge during the time frame.
MarketWatch.com - Top Stories, MarketWatch
Mon, 01/18/2021 - 10:00am
Baillie Gifford U.S. Growth Trust devoted much of its half-yearly report to talking up the prospects of biotech Moderna and rocket launcher SpaceX, two of its investments that helped lift its net asset value surge during the time frame.